Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices to Buy Axon Instruments for $140M in Cash and Stock

NEW YORK, March 22 (GenomeWeb News) - Molecular Devices plans to acquire Axon Instruments for a total of $140 million in cash and stock, the company said yesterday.

 

Molecular Devices, based in Sunnyvale, Calif., hopes the acquisition will create synergies for product development and will help distribute Axon's products more effectively.

 

Molecular Devices will pay approximately $70 million in cash and $70 million of its common stock for Axon, including Axon's $29 million in cash and marketable securities. Under the agreement, each Axon share of common stock would be converted into approximately $.14 in cash and 0.007 of a Molecular Devices share.

 

Axon, which makes instruments for electrophysiology as well as microarray scanners, is based in Union City, Calif. and has 128 employees. The acquisition is subject to a number of conditions, including shareholder approval from both companies, and is expected to close by the end of June.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.